{"nctId":"NCT00702650","briefTitle":"A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations","startDateStruct":{"date":"2008-06"},"conditions":["Hypogonadism"],"count":155,"armGroups":[{"label":"Testosterone MD-Lotion","type":"EXPERIMENTAL","interventionNames":["Drug: Testosterone MD-Lotion"]}],"interventions":[{"name":"Testosterone MD-Lotion","otherNames":["LY900011","Axiron"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male subjects with a prior documented definitive diagnosis of hypogonadism as evidenced by previously documented:\n\n  * Hypothalamic, pituitary or testicular disorder or age related idiopathic hypogonadism\n  * Screening serum testosterone of less than or equal to 300 ng/dL (based on the average of two morning samples taken at least 30 minutes apart)\n* Were currently receiving treatment for hypogonadism in accordance with approved labelling, or in the Investigator's opinion are eligible to receive such treatment\n* Body Mass Index (BMI) \\< 35.0 kg/m\\^2\n* Haemoglobin levels at screening greater than or equal to 11.5 g/dL\n* Adequate venous access on left or right arm to allow collection of a number of samples by venipuncture\n* Ability to communicate with the trial staff, understand the Trial Information Sheet and sign the Written Informed Consent Forms; willing to follow the Protocol requirements and comply with Protocol restrictions and procedures\n\nExclusion Criteria:\n\n* Current use of long acting testosterone injectables such as NebidoÂ®\n* Any significant history of allergy and/or sensitivity to the drug products or their excipients, including any history of sensitivity to testosterone and/or sunscreens\n* Any clinically significant chronic illness or finding on screening physical exam and/or laboratory testing that makes it undesirable for the Investigator to enrol the trial subject in the trial and/or that in the Investigator's opinion, would interfere with the trial objectives or safety of the subject\n* Chronic skin disorder (e.g. eczema, psoriasis) likely to interfere with transdermal drug absorption\n* Men with suspected reversible hypogonadism\n* Any man in whom testosterone therapy was contraindicated, which included those with:\n\n  * Known or suspected carcinoma (or history of carcinoma) of the prostate or clinically significant symptoms of benign prostatic hyperplasia and/or clinically significant symptoms of lower urinary obstruction and International Prostate Symptom Scores (IPSS) scores of greater than or equal to 19\n  * Known or suspected carcinoma (or history of carcinoma) of the breast\n  * Severe liver disease (i.e. cirrhosis, hepatitis or liver tumours or liver function tests \\>2 times the upper limit of the normal range values)\n  * Active deep vein thrombosis, thromboembolic disorders or a documented history of these conditions\n  * Current significant cerebrovascular or coronary artery disease\n  * Untreated sleep apnoea\n  * Haematocrit of \\> 51\n  * Untreated moderate to severe depression\n* Men with clinically significant prostate exam (such as irregularities or nodules palpated) or clinically significant elevated serum Prostate Specific Antigen (PSA) levels (\\>4 ng/mL), or age adjusted reference range of PSA values\n* Current or history of drug or alcohol abuse (more than 4 standard drinks per day and/or abnormal liver function tests \\>2 times the upper limit of the normal range values)\n* Men taking concomitant medications (prescribed, over-the-counter or complementary) that would affect sex hormone binding globulin (SHBG) or testosterone concentrations or metabolism, warfarin, insulin, opiates, Gonadotropin-releasing hormone (GnRH), 5 alpha reductase inhibitors, propanolol, oxyphenbutazone, corticosteroids (except for physiological replacement doses), estradiol\n* Men involved in sport in which there is screening for anabolic steroids\n* Men with uncontrolled diabetes (haemoglobin A1c \\[HbA1c\\] greater than or equal to 10%)\n* Men currently taking any investigational product, or have received an investigational product within 28 days prior to screening or 5 half-lives\n* Any contraindication to blood sampling\n* Subjects intending to have any surgical procedure during the course of the trial\n* Subjects with a partner of child bearing potential who are not willing to use adequate contraception for the duration of the trial\n* Subjects whose partners are pregnant","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With 24-Hour Average Concentration [Cavg(0-24h)] Total Testosterone Within Normal Range at Day 120","description":"Cavg(0-24) is the average serum concentration calculated over the 24 hour period on Day 120. Calculated as the AUC(0-24) divided by 24 hours. Normal range for Total Testosterone was defined as 300 - 1050 nanograms per deciliter (ng/dL).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Maximum Serum Concentration (Cmax) >1500 ng/dL","description":"Cmax is the maximum observed serum concentration (\\>1500 ng/dL) during the 24 hour period on Day 120.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Cmax Between 1800 and 2500 ng/dL","description":"Cmax is the maximum observed serum concentration (between 1800 and 2500 ng/dL) during the 24 hour period on Day 120.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Cmax >2500 ng/dL","description":"Cmax is the maximum observed serum concentration (\\>2500 ng/dL) during the 24 hour period on Day 120.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Minimum Concentration (Cmin) <300 ng/dL","description":"Cmin is the minimum observed serum concentration (\\<300 ng/dL) during the 24 hour period on Day 120.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Psychosexual Daily Questionnaire","description":"Questions included: Sexual Desire (0=none to 7=very high), Overall Sexual Activity Score (calculated as average of weekly values on scale from 0=none to 7=Frequent), Erection Maintained for Satisfactory Duration (0=not satisfactory to 7=very satisfactory), and Positive and Negative Mood (individual mood variables on scale from 0=Not at all true to 7=very true). Positive mood: sum of 4 positive mood variables-alert, full of pep/energetic, friendly, and well/good (range from 0-28). Negative mood: sum of 5 negative mood variables-angry, irritable, sad/blue, tired, and nervous (range from 0-35).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":"1.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"1.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"1.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"1.33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in the 36-Item Short-Form Health Survey (SF-36)","description":"The SF-36 Health Status Survey is a generic, health-related scale assessing subjects' quality of life on 8 domains: physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health and 2 summary scores (mental component summary \\[MCS\\] and physical component summary \\[PCS\\]). MCS and PCS scores=0-100 (higher scores indicate better health status).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"7.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.54","spread":"9.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Fasting Insulin","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.93","spread":"12.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Fasting Glucose","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"20.02"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Prostate Specific Antigen (PSA)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.68"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"5.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.41","spread":"9.72"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Estradiol","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.16","spread":"12.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Haemoglobin","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"1.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Haematocrit","description":"Haematocrit: percentage of total blood volume made up of blood cells","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Endpoint in Draize Score","description":"Draize score is a measurement of skin irritability of the application site based on erythema/eschar and oedema. Erythema/eschar scoring ranges from 0 (no erythema) to 4 (severe erythema \\[beet redness\\] to slight eschar formation \\[injuries in depth\\]). Oedema scoring ranges from 0 (no oedema) to 4 (severe oedema \\[raised more than 1 millimeter and extending beyond area of exposure\\]. The total Draize score ranges from 0 to 8.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.17"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":155},"commonTop":["Application site irritation","Application site erythema","Headache","Nasopharyngitis","Haematocrit increased"]}}}